Determination of serum anti-Mullerian hormone levels in a low-prognosis women treated in-vitro fertilization/intracytoplasmic sperm injection: A cohort study.

IF 1.6 Q3 OBSTETRICS & GYNECOLOGY International Journal of Reproductive Biomedicine Pub Date : 2023-04-14 eCollection Date: 2023-03-01 DOI:10.18502/ijrm.v21i3.13201

Ferdy Royland Marpaung, Amang Surya Priyanto, Fitri Ayu Kusumawati, Sidarti Soehita, Aryati

{"title":"Determination of serum anti-Mullerian hormone levels in a low-prognosis women treated in-vitro fertilization/intracytoplasmic sperm injection: A cohort study.","authors":"Ferdy Royland Marpaung, Amang Surya Priyanto, Fitri Ayu Kusumawati, Sidarti Soehita, Aryati","doi":"10.18502/ijrm.v21i3.13201","DOIUrl":null,"url":null,"abstract":"Background: Outcome prediction of participants treated with in-vitro fertilization or intracytoplasmic sperm injection (IVF/ICSI) using anti-Mullerian hormone (AMH) concentration has been widely used. According to the patient-oriented strategies encompassing individualized oocyte number (POSEIDON) definition, low prognosis Bologna responders have changed from poor. This definition divides low prognosis into 4 groups.Objective: The purpose of this study was to assess blood AMH levels in the group of women treated with IVF/ICSI who were thought to have a low prognosis.Materials and methods: A retrospective cohort study among 252 suspected low-prognosis group participants was assessed between January 2016 and December 2019 at Morula IVF, National hospital, Surabaya, Indonesia. Observed AMH serum levels and pregnancy rates were compared among 4 subgroups.Results: The AMH cutoff value was 1.7 ng/mL with a sensitivity of 86.7% and a specificity of 70% for diagnosing low-prognosis women using POSEIDON criteria. There was no difference in the pregnancy rate between those groups (p <math><mo>></mo></math> 0.05).Conclusion: AMH levels may indicate a poor prognosis for women having IVF/ICSI in accordance with POSEIDON guidelines. To predict the poor prognosis in women, the cutoff value must be identified.","PeriodicalId":14386,"journal":{"name":"International Journal of Reproductive Biomedicine","volume":null,"pages":null},"PeriodicalIF":1.6000,"publicationDate":"2023-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10133738/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Reproductive Biomedicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18502/ijrm.v21i3.13201","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/3/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Outcome prediction of participants treated with in-vitro fertilization or intracytoplasmic sperm injection (IVF/ICSI) using anti-Mullerian hormone (AMH) concentration has been widely used. According to the patient-oriented strategies encompassing individualized oocyte number (POSEIDON) definition, low prognosis Bologna responders have changed from poor. This definition divides low prognosis into 4 groups.

Objective: The purpose of this study was to assess blood AMH levels in the group of women treated with IVF/ICSI who were thought to have a low prognosis.

Materials and methods: A retrospective cohort study among 252 suspected low-prognosis group participants was assessed between January 2016 and December 2019 at Morula IVF, National hospital, Surabaya, Indonesia. Observed AMH serum levels and pregnancy rates were compared among 4 subgroups.

Results: The AMH cutoff value was 1.7 ng/mL with a sensitivity of 86.7% and a specificity of 70% for diagnosing low-prognosis women using POSEIDON criteria. There was no difference in the pregnancy rate between those groups (p $>$ 0.05).

Conclusion: AMH levels may indicate a poor prognosis for women having IVF/ICSI in accordance with POSEIDON guidelines. To predict the poor prognosis in women, the cutoff value must be identified.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

体外受精/卵胞浆内单精子注射低预后妇女血清抗穆勒氏管激素水平的测定：一项队列研究。

背景：使用抗穆勒氏管激素（AMH）浓度预测体外受精或卵胞浆内单精子显微注射（IVF/ICSI）参与者的结果已被广泛使用。根据包含个体化卵母细胞数的患者导向策略（POSEIDON）的定义，低预后博洛尼亚反应者已从贫困者转变而来。该定义将低预后分为 4 组：本研究的目的是评估接受体外受精/卵胞浆内单精子显微注射（IVF/ICSI）治疗、被认为预后较差的妇女群体的血液AMH水平：2016年1月至2019年12月期间，印度尼西亚泗水国立医院Morula IVF对252名疑似低预后组参与者进行了回顾性队列研究评估。对4个亚组的观察AMH血清水平和妊娠率进行了比较：采用POSEIDON标准诊断低预后妇女的AMH临界值为1.7纳克/毫升，灵敏度为86.7%，特异度为70%。两组之间的妊娠率没有差异（P > 0.05）：结论：根据POSEIDON指南，AMH水平可能预示着IVF/ICSI女性的不良预后。要预测妇女的不良预后，必须确定临界值。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

International Journal of Reproductive Biomedicine OBSTETRICS & GYNECOLOGY-

CiteScore

2.40

自引率

7.70%

发文量

审稿时长

16 weeks

期刊介绍： The International Journal of Reproductive BioMedicine (IJRM), formerly published as "Iranian Journal of Reproductive Medicine (ISSN: 1680-6433)", is an international monthly scientific journal for who treat and investigate problems of infertility and human reproductive disorders. This journal accepts Original Papers, Review Articles, Short Communications, Case Reports, Photo Clinics, and Letters to the Editor in the fields of fertility and infertility, ethical and social issues of assisted reproductive technologies, cellular and molecular biology of reproduction including the development of gametes and early embryos, assisted reproductive technologies in model system and in a clinical environment, reproductive endocrinology, andrology, epidemiology, pathology, genetics, oncology, surgery, psychology, and physiology. Emerging topics including cloning and stem cells are encouraged.